β- 內啡肽在增生性瘢痕組織中的表達及其與瘢痕瘙癢關系的研究_《中國修復重建外科雜志》

作者：

朱江婷 ^1,2 , 程飚 ² , 劉宏偉 ³ , 唐建兵 ² , 項曉飛 ² , 彭艷 ²

1 南方醫科大學研究生學院（廣州，510515）;;
2 廣州軍區廣州總醫院整形外科全軍熱區創傷救治與組織修復重點實驗室;;
3 暨南大學附屬第一醫院整形外科組織再生教育部重點實驗室;

關鍵詞：

增生性瘢痕 β - 內啡肽感覺異常阿片肽

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的阿片肽與增生性瘢痕患者感覺異常有關，通過比較β- 內啡肽在人正常皮膚與增生性瘢痕組織中的表達情況，探討其在增生性瘢痕感覺異常發生、發展中所起作用。方法取42 例增生性瘢痕患者自愿捐贈的增生性瘢痕組織；男15 例，女27 例；年齡16 ～ 50 歲，平均32.6 歲；瘢痕形成時間1 ～ 20 年，平均4.5 年。根據患者感覺情況，將瘢痕組織分為3 組，無痛癢組（n=20）、單純癢組（n=14）及痛癢組（n=8）。另取行植皮手術患者自愿捐贈的正常皮膚組織5 例作為正常對照組，男3 例，女2 例；年齡15 ～ 37 歲，平均24.6 歲。采用免疫熒光染色觀察β- 內啡肽定位情況，ELISA 法檢測組織中β- 內啡肽含量。結果各組組織中均可見β- 內啡肽表達，主要位于真皮層周圍神經末梢、成纖維細胞和單核樣細胞；其中單純癢組和痛癢組β- 內啡肽表達明顯強于無痛癢組與正常對照組。無痛癢組、單純癢組、痛癢組及正常對照組組織β- 內啡肽含量分別為（617.401 ± 97.518）、（739.543 ± 94.149）、（623.294 ± 149.613）、（319.734 ± 85.301）pg/ mL，其中無痛癢組、單純癢組及痛癢組β- 內啡肽含量均顯著高于正常皮膚組（P lt; 0.05），單純癢組高于無痛癢組及痛癢組（P lt; 0.05），無痛癢組與痛癢組間差異無統計學意義（P gt; 0.05）。結論增生性瘢痕中β- 內啡肽的高表達，可能與其瘙癢發生有關。

引用本文： 朱江婷,程飚,劉宏偉,唐建兵,項曉飛,彭艷. β- 內啡肽在增生性瘢痕組織中的表達及其與瘢痕瘙癢關系的研究. 中國修復重建外科雜志, 2012, 26(6): 731-734. doi: 復制

1.	Profyris C, Tziotzios C, Do Vale I, et al. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. J Am Acad Dermatol, 2012, 66(1): 1-10.
2.	Akaishi S, Ogawa R, Hyakusoku H. Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses, 2008, 71(1): 32-38.
3.	Pitzer GB, Patel KG. Proper care of early wounds to optimize healing and prevent complications. Facial Plast Surg Clin North Am, 2011, 19(3): 491-504.
4.	Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011, 17(1-2): 113-125.
5.	程飚, 劉宏偉, 李勤, 等. β-內啡肽與μ-阿片受體在正常皮膚與增生性瘢痕組織中的分布特征與生物學意義. 中華整形外科雜志, 2008, 24(5): 343-346.
6.	葉巧園, 樊翌明. P物質、蛋白酶、阿片樣肽3種非組胺依賴性瘙癢介質的研究進展. 廣東醫學院學報, 2008, 26(5): 553-556.
7.	Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, et al. Opioids and the skin—where do we stand? Exp Dermatol, 2009, 18(5): 424-430.
8.	劉莉萍, 范衛新. β-內啡肽在皮膚中的作用. 臨床皮膚科雜志, 2006, 35(3): 192-193.
9.	Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology, 2004, 209(3): 183-189.
10.	Cheng B, Liu HW, Fu XB, et al. Update on pruritic mechanisms of hypertrophic scars in postburn patients: the potential role of opioids and their receptors. J Burn Care Res, 2011, 32(4): e118-125.
11.	Van Loey NE, Bremer M, Faber AW, et al. Itching following burns: epidemiology and predictors. Br J Dermatol, 2008, 158(1): 95-100.
12.	Nelson RD. Postburn itch//Yosipovitch G, Greaves MW, Fleischer AB, et al. Itch: basic mechanism and therapy. New York: Marcel Dekker, 2004: 247-254.
13.	Forbes-Duchart L, Cooper J, Nedelec B, et al. Burn therapists’ opinion on the application and essential characteristics of a burn scar outcome measure. J Burn Care Res, 2009, 30(5): 792-800.
14.	Bigliardi-Qi M, Lipp B, Sumanovski LT, et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology, 2005, 210(2): 91-99.
15.	Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol, 2011, 165(2): 277-284.
16.	Cheng B, Liu HW, Fu XB, et al. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol, 2008, 158(4): 713-720.
17.	Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci, 2006, 7(7): 535-547.
18.	Goutos I. Burns pruritus—a study of current practices in the UK. Burns, 2010, 36(1): 42-48.
19.	Baker RA, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil, 2008, 22(4): 263-268.

1. Profyris C, Tziotzios C, Do Vale I, et al. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. J Am Acad Dermatol, 2012, 66(1): 1-10.
2. Akaishi S, Ogawa R, Hyakusoku H. Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses, 2008, 71(1): 32-38.
3. Pitzer GB, Patel KG. Proper care of early wounds to optimize healing and prevent complications. Facial Plast Surg Clin North Am, 2011, 19(3): 491-504.
4. Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011, 17(1-2): 113-125.
5. 程飚, 劉宏偉, 李勤, 等. β-內啡肽與μ-阿片受體在正常皮膚與增生性瘢痕組織中的分布特征與生物學意義. 中華整形外科雜志, 2008, 24(5): 343-346.
6. 葉巧園, 樊翌明. P物質、蛋白酶、阿片樣肽3種非組胺依賴性瘙癢介質的研究進展. 廣東醫學院學報, 2008, 26(5): 553-556.
7. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, et al. Opioids and the skin—where do we stand? Exp Dermatol, 2009, 18(5): 424-430.
8. 劉莉萍, 范衛新. β-內啡肽在皮膚中的作用. 臨床皮膚科雜志, 2006, 35(3): 192-193.
9. Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology, 2004, 209(3): 183-189.
10. Cheng B, Liu HW, Fu XB, et al. Update on pruritic mechanisms of hypertrophic scars in postburn patients: the potential role of opioids and their receptors. J Burn Care Res, 2011, 32(4): e118-125.
11. Van Loey NE, Bremer M, Faber AW, et al. Itching following burns: epidemiology and predictors. Br J Dermatol, 2008, 158(1): 95-100.
12. Nelson RD. Postburn itch//Yosipovitch G, Greaves MW, Fleischer AB, et al. Itch: basic mechanism and therapy. New York: Marcel Dekker, 2004: 247-254.
13. Forbes-Duchart L, Cooper J, Nedelec B, et al. Burn therapists’ opinion on the application and essential characteristics of a burn scar outcome measure. J Burn Care Res, 2009, 30(5): 792-800.
14. Bigliardi-Qi M, Lipp B, Sumanovski LT, et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology, 2005, 210(2): 91-99.
15. Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol, 2011, 165(2): 277-284.
16. Cheng B, Liu HW, Fu XB, et al. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol, 2008, 158(4): 713-720.
17. Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci, 2006, 7(7): 535-547.
18. Goutos I. Burns pruritus—a study of current practices in the UK. Burns, 2010, 36(1): 42-48.
19. Baker RA, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil, 2008, 22(4): 263-268.

《中國修復重建外科雜志》

β- 內啡肽在增生性瘢痕組織中的表達及其與瘢痕瘙癢關系的研究

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國修復重建外科雜志》

β- 內啡肽在增生性瘢痕組織中的表達及其與瘢痕瘙癢關系的研究

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料